THE podcast: What does it take to successfully commercialise research?

Campus by Times Higher Education

A technology transfer expert and biotech spin-out founder explain the steps involved in moving discoveries from the lab to the market.

Most academics want their work to have an impact and one route to achieving this is by commercialising their findings. By partnering with an existing company to bring a product to market or by establishing a new spin-out enterprise, scholars can develop technologies, products and solutions that can revolutionise whole sectors, whether in healthcare, construction, farming and more. But this is a far from easy or simple process requiring tenacity, adaptability, collaboration and high level problem solving.

For this week’s podcast, we speak to two people with extensive experience in what it takes to commercialise research and become an academic entrepreneur.

Mairi Gibbs is CEO of Oxford University Innovation – the university’s technology transfer unit - where she has worked since 2002. With extensive practical experience in partnership management, formation of spinout companies, licensing and patent portfolio management, she explains the initial steps to commercialisation, what investors look for and what can be done at an institutional level to support more spin out activity.

Andrew Hammond is co-founder and head of R&D at Biocentis – an Imperial College London spin out founded in 2022. With a background in molecular biology, Andrew’s 10-year academic career at both Imperial and Johns Hopkins University involved advancing gene editing technology for use in insects. The resulted in the development of gene drive technology designed for use on malaria mosquitos and the later development of Biocentis.

For more advice and insight on this topic, read our spotlight guide on how to work well with industry.